SELLAS Positive Trial Data, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 02/29/20
SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)GlobeNewsWire • 02/26/20
SELLAS Life Sciences Provides Regulatory Update for Nelipepimut-S (NPS) for Triple Negative Breast Cancer (TNBC) Following FDA FeedbackGlobeNewsWire • 02/14/20
SELLAS Announces Enrollment of First Patient in Phase 1 Trial of Galinpepimut-S (GPS) in Combination with Nivolumab (Opdivo®) in Patients with Malignant Pleural Mesothelioma (MPM)GlobeNewsWire • 02/11/20
SELLAS Names Dragan Cicic, MD, as Senior Vice President, Clinical DevelopmentGlobeNewsWire • 02/10/20
SELLAS Announces Pricing of $6.5 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 01/09/20
SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML)GlobeNewsWire • 01/08/20